Spots Global Cancer Trial Database for platinum resistant ovarian cancer
Every month we try and update this database with for platinum resistant ovarian cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | NCT03940196 | Ovarian Cancer | NovoTTF-100L(O) Paclitaxel | 18 Years - | NovoCure Ltd. | |
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | NCT03940196 | Ovarian Cancer | NovoTTF-100L(O) Paclitaxel | 18 Years - | NovoCure Ltd. | |
| A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | NCT01711970 | Platinum Resist... | Paclitaxel | 18 Years - | Vascular Biogenics Ltd. operating as VBL Therapeutics | |
| Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors | NCT00569257 | Ovarian Cancer Endometrial Can... | AEZS-108 | 18 Years - | AEterna Zentaris | |
| First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | NCT03319628 | Platinum Resist... Non Small Cell ... | upifitamab rils... | 18 Years - | Mersana Therapeutics | |
| First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | NCT03319628 | Platinum Resist... Non Small Cell ... | upifitamab rils... | 18 Years - | Mersana Therapeutics | |
| Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT03552471 | BRCA1 Gene Muta... BRCA2 Gene Muta... Folate Receptor... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Uteri... Recurrent Uteri... Platinum Resist... | Laboratory Biom... Mirvetuximab So... Pharmacokinetic... Rucaparib Camsy... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | NCT02641639 | Platinum Resist... | Fosbretabulin t... Placebo | 18 Years - | Mateon Therapeutics | |
| Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | NCT01104675 | Ovarian Cancer Fallopian Cance... Peritoneal Canc... | ENMD-2076 | 18 Years - | CASI Pharmaceuticals, Inc. | |
| Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | NCT01202890 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Primary Periton... | Lenalidomide, L... Revlimid, Doxil... | - | New Mexico Cancer Care Alliance | |
| Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | NCT00343044 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Topotecan Bevacizumab | 18 Years - | Benaroya Research Institute | |
| A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | NCT01711970 | Platinum Resist... | Paclitaxel | 18 Years - | Vascular Biogenics Ltd. operating as VBL Therapeutics | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors | NCT00569257 | Ovarian Cancer Endometrial Can... | AEZS-108 | 18 Years - | AEterna Zentaris | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | NCT00343044 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Topotecan Bevacizumab | 18 Years - | Benaroya Research Institute | |
| FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | NCT02641639 | Platinum Resist... | Fosbretabulin t... Placebo | 18 Years - | Mateon Therapeutics | |
| Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | NCT01202890 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Primary Periton... | Lenalidomide, L... Revlimid, Doxil... | - | New Mexico Cancer Care Alliance | |
| Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT03552471 | BRCA1 Gene Muta... BRCA2 Gene Muta... Folate Receptor... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Uteri... Recurrent Uteri... Platinum Resist... | Laboratory Biom... Mirvetuximab So... Pharmacokinetic... Rucaparib Camsy... | 18 Years - | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
